Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.

Davies, Melanie J

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents. [electronic resource] - Diabetes, obesity & metabolism 12 2017 - 1798-1804 p. digital

Publication Type: Comparative Study; Equivalence Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1463-1326

10.1111/dom.12980 doi


Body Mass Index
Diabetes Mellitus, Type 2--complications
Disease Progression
Drug Combinations
Drug Resistance
Drug Therapy, Combination--adverse effects
Glucagon-Like Peptide-1 Receptor--metabolism
Glycated Hemoglobin--analysis
Humans
Hyperglycemia--prevention & control
Hypoglycemia--chemically induced
Insulin Glargine--administration & dosage
Middle Aged
Obesity--complications
Peptides--administration & dosage
Postprandial Period
Weight Gain--drug effects
Glucagon-Like Peptide-1 Receptor Agonists